

# Dosing of LT4 in Older Individuals

NCT06073665

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	University of Pennsylvania
<b>Enrollment</b>	228 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, community dwelling, aged 65 years or older
- Diagnosed with hypothyroidism of any etiology for at least 6 months, taking 75-200 mcg per day LT4 and a minimum of 1.2 mcg/kg/day with no dose adjustment since the last TSH test.
- Ability to take oral medication and be willing to adhere to the medication regimen

... and 1 more (see full listing online)

### Exclusion (8)

- Hypopituitarism
- History of thyroid cancer requiring suppression of TSH secretion
- Current use of liothyronine (LT3), thyroid extracts, Tirosint liquid or capsules, and medications that interfere with thyroid function or thyroid function tests
- GFR  $\leq$ 30 ml/min/1.73 m<sup>2</sup> within the prior 12 months
- Unable to understand and comply with study requirements, as assessed by study staff and the PI, will be excluded.

... and 3 more (see full listing online)

## Locations (1 total)

---

Penn Medicine, Smilow Translational Research Center, Philadelphia, Pennsylvania, United States